The pharmaceutical industry is on the brink of vigorous expansion, driven by an ever-growing medicinal drug and vaccine market. The industry maintains stability due to the unabated demand for its offerings, making it less susceptible to economic volatility.
Given this backdrop, investors could consider buying fundamentally robust pharma stocks Organon & Co. (OGN), GoodRx Holdings, Inc. (GDRX), and Collegium Pharmaceutical, Inc. (COLL) this week.
